{
  "abstract": "Transcriptomic response biomarkers for immune-checkpoint blockade remain poorly defined across cancers. We developed the two-gene Myeloid-Adaptive Response to Atezolizumab (MARTA) score, integrating CXCL13 and CXCL8 expression. MARTA was developed in 81 atezolizumab-treated patients in IMmotion150, evaluated across treatment groups, and independently assessed in IMvigor210. In IMmotion150, higher MARTA was associated with higher objective response rate (ORR) with atezolizumab alone (odds ratio [OR], 3.20; 95% confidence interval [CI], 1.42–7.19) and atezolizumab plus bevacizumab (OR, 2.61; 95% CI, 1.43–4.76), but not with sunitinib. Higher MARTA was associated with longer progression-free survival (PFS) in both atezolizumab-containing groups (hazard ratio [HR], 0.60 and 0.65), but not with sunitinib (interaction p = 0.01). In IMvigor210, higher MARTA was associated with higher ORR (OR per 1-standard-deviation increase, 1.38; 95% CI, 1.05–1.81) and longer overall survival (OS) (HR, 0.76; 95% CI, 0.67–0.86). The OS association remained after multivariate adjustment (HR, 0.81; 95% CI, 0.69–0.95). Discrimination for ORR and OS, assessed by the area under the curve (AUC) and C-index, respectively, was modest for MARTA, tGE8, and the IFN-γ signature. These findings support further evaluation of MARTA, while prospective validation and cross-platform analytical reproducibility remain necessary before clinical application.",
  "abstract_shown": true,
  "affiliations": [
    "Royal United Hospitals Bath NHS Foundation Trust, Bath BA1 3NG, UK"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 1,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Mario Uccello"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/5es6mwhk16vek.bib",
  "cited_by": 0,
  "doi": "10.3390/cimb48101012",
  "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13703666/?tool=EBI",
  "id": "5es6mwhk16vek",
  "issns": [
    "1467-3037",
    "1467-3045"
  ],
  "landing_url": "https://europepmc.org/article/PMC/PMC13703666",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "QH301-705.5"
    ],
    [
      "openalex",
      "2730|Cancer Immunotherapy and Biomarkers"
    ]
  ],
  "openalex": "W7204077575",
  "pdf_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13703666/pdf/?tool=EBI",
  "pmcid": "PMC13703666",
  "pmid": null,
  "published": "2026-10-01",
  "publisher": "MDPI AG",
  "ris": "https://research.draconitic.com/paper/5es6mwhk16vek.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:21:25Z",
      "native_id": "PMC:PMC13703666",
      "source": "europepmc",
      "url": "https://europepmc.org/article/PMC/PMC13703666"
    },
    {
      "first_seen": "2026-10-31T14:21:26Z",
      "native_id": "05e7d7a7d1d845c7842bc480f072a807",
      "source": "doaj",
      "url": "https://doi.org/10.3390/cimb48101012"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Cancer Immunotherapy and Biomarkers",
      "subfield": "oncology"
    }
  ],
  "title": "Myeloid-Adaptive Response to Atezolizumab (MARTA): A Two-Gene CXCL13–CXCL8 Transcriptomic Biomarker Across Renal Cell and Urothelial Carcinoma",
  "title_text": "Myeloid-Adaptive Response to Atezolizumab (MARTA): A Two-Gene CXCL13–CXCL8 Transcriptomic Biomarker Across Renal Cell and Urothelial Carcinoma",
  "type": "peer-reviewed",
  "updated_at": "2026-10-31T14:21:26Z",
  "url": "https://research.draconitic.com/paper/5es6mwhk16vek",
  "venue": "Current issues in molecular biology",
  "versions": []
}